Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer

NCT02275039 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02275039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02275039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
February 6, 2015
Completion date
April 23, 2018
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent fallopian tube carcinoma, recurrent ovarian epithelial cancer, recurrent primary peritoneal carcinoma